• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU 1.95% $15.15

NEUREN PHARMACEUTICALS LIMITED

Healthcare

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company that is... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company that is engaged in developing drugs for neurological disorders. The Company’s lead drug compound, Trofinetide, is in a Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. Its both programs have each received Fast Track designation by the United States Food and Drug Administration (FDA) and Orphan Drug designation in both the United States and the European Union. The Company has granted a license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, while retaining all rights outside North America. The Company is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
NEU
Share Price
06:28 8.0K 3.4M
06:28 Last post  giarc63 Comments Created with Sketch.  8.0K  Views Created with Sketch.  3.4M 
NEU
NEU chart
18 19 20
28/11/23 1.1K 580K
28/11/23 Last post  pglynn Comments Created with Sketch.  1.1K  Views Created with Sketch.  580K 
NEU 28/11/23 42 20K
TRENDING NEWS

Wealth Within’s Hot Stock Tips launches in partnership with HotCopper and The Market Herald

NEWS
28 Nov 2023
28/11/23 Last post  turbo Comments Created with Sketch.  42  Views Created with Sketch.  20K 
NEU
Acadia
9 10 11
28/11/23 645 296K
28/11/23 Last post  Piton72 Comments Created with Sketch.  645  Views Created with Sketch.  296K 
NEU
Merck to acquire Prometheus in a US$ 10.8 b deal
27/11/23 21 11K
27/11/23 Last post  Wasabibarako Comments Created with Sketch.  21  Views Created with Sketch.  11K 
NEU
Neuren Media and Analyst Coverage
7 8 9
25/11/23 515 256K
25/11/23 Last post  ashgood123 Comments Created with Sketch.  515  Views Created with Sketch.  256K 
NEU
the game is ON
2 3
24/11/23 123 55K
24/11/23 Last post  nashezz Comments Created with Sketch.  123  Views Created with Sketch.  55K 
NEU
Autism
24/11/23 1 1.1K
24/11/23 Last post  perthpest Comments Created with Sketch.  1  Views Created with Sketch.  1.1K 

See All Discussions arrow Created with Sketch.

Timeline

Comment on media speculation
20 Nov 10:14
 
Neuren completes Phelan-McDermid syndrome Phase 2 trial
13 Nov 09:45
 
Investor presentation, 8 November 2023
08 Nov 09:20
 
DAYBUE net sales US$66.9 million in Q3 2023
03 Nov 09:59
 
Q3 2023 quarterly activity and cash flow report
20 Oct 09:30
 
Change of Director's Interest Notice - J Basile
14 Sep 09:19
 
View More arrow Created with Sketch.
(20min delay)
Last
$15.15
Change
0.290(1.95%)
Mkt cap ! $1.917B
Open High Low Value Volume
$15.10 $15.30 $14.93 $11.27M 745.2K

Buyers (Bids)

No. Vol. Price($)
2 1269 $15.13
 

Sellers (Offers)

Price($) Vol. No.
$15.16 501 1
View Market Depth
Last trade - 16.10pm 28/11/2023 (20 minute delay) ?
Last
$15.14
  Change
0.290 ( 1.73 %)
Open High Low Volume
$15.10 $15.29 $14.92 84680
Last updated 15.59pm 28/11/2023 ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.